308 related articles for article (PubMed ID: 21630308)
1. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.
Kumar SK; Lacy MQ; Hayman SR; Stewart K; Buadi FK; Allred J; Laumann K; Greipp PR; Lust JA; Gertz MA; Zeldenrust SR; Bergsagel PL; Reeder CB; Witzig TE; Fonseca R; Russell SJ; Mikhael JR; Dingli D; Rajkumar SV; Dispenzieri A
Am J Hematol; 2011 Aug; 86(8):640-5. PubMed ID: 21630308
[TBL] [Abstract][Full Text] [Related]
2. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Khan ML; Reeder CB; Kumar SK; Lacy MQ; Reece DE; Dispenzieri A; Gertz MA; Greipp P; Hayman S; Zeldenhurst S; Dingli D; Lust J; Russell S; Laumann KM; Mikhael JR; Leif Bergsagel P; Fonseca R; Vincent Rajkumar S; Keith Stewart A
Br J Haematol; 2012 Feb; 156(3):326-33. PubMed ID: 22107129
[TBL] [Abstract][Full Text] [Related]
3. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Jakubowiak AJ; Griffith KA; Reece DE; Hofmeister CC; Lonial S; Zimmerman TM; Campagnaro EL; Schlossman RL; Laubach JP; Raje NS; Anderson T; Mietzel MA; Harvey CK; Wear SM; Barrickman JC; Tendler CL; Esseltine DL; Kelley SL; Kaminski MS; Anderson KC; Richardson PG
Blood; 2011 Jul; 118(3):535-43. PubMed ID: 21596852
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
Gay F; Hayman SR; Lacy MQ; Buadi F; Gertz MA; Kumar S; Dispenzieri A; Mikhael JR; Bergsagel PL; Dingli D; Reeder CB; Lust JA; Russell SJ; Roy V; Zeldenrust SR; Witzig TE; Fonseca R; Kyle RA; Greipp PR; Stewart AK; Rajkumar SV
Blood; 2010 Feb; 115(7):1343-50. PubMed ID: 20008302
[TBL] [Abstract][Full Text] [Related]
6. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Wilson JN; Jenner MW; Cook G; Kaiser MF; Drayson MT; Owen RG; Russell NH; Gregory WM; Morgan GJ;
Lancet Haematol; 2019 Dec; 6(12):e616-e629. PubMed ID: 31624047
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.
Kumar SK; Hayman SR; Buadi FK; Roy V; Lacy MQ; Gertz MA; Allred J; Laumann KM; Bergsagel LP; Dingli D; Mikhael JR; Reeder CB; Stewart AK; Zeldenrust SR; Greipp PR; Lust JA; Fonseca R; Russell SJ; Rajkumar SV; Dispenzieri A
Blood; 2012 May; 119(21):4860-7. PubMed ID: 22504925
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Niesvizky R; Martin TG; Bensinger WI; Alsina M; Siegel DS; Kunkel LA; Wong AF; Lee S; Orlowski RZ; Wang M
Clin Cancer Res; 2013 Apr; 19(8):2248-56. PubMed ID: 23447001
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Jackson GH; Pawlyn C; Cairns DA; de Tute RM; Hockaday A; Collett C; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Rocci A; Snowden JA; Jenner MW; Cook G; Russell NH; Drayson MT; Gregory WM; Kaiser MF; Owen RG; Davies FE; Morgan GJ;
PLoS Med; 2021 Jan; 18(1):e1003454. PubMed ID: 33428632
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study.
Kwon J; Min CK; Kim K; Han JJ; Moon JH; Kang HJ; Eom HS; Kim MK; Kim HJ; Yoon DH; Lee JO; Lee WS; Lee JH; Lee JJ; Choi YS; Kim SH; Yoon SS
Cancer Med; 2017 Jan; 6(1):100-108. PubMed ID: 27905203
[TBL] [Abstract][Full Text] [Related]
12. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Lentzsch S; O'Sullivan A; Kennedy RC; Abbas M; Dai L; Pregja SL; Burt S; Boyiadzis M; Roodman GD; Mapara MY; Agha M; Waas J; Shuai Y; Normolle D; Zonder JA
Blood; 2012 May; 119(20):4608-13. PubMed ID: 22451423
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702
[TBL] [Abstract][Full Text] [Related]
15. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
[TBL] [Abstract][Full Text] [Related]
16. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Niesvizky R; Jayabalan DS; Christos PJ; Furst JR; Naib T; Ely S; Jalbrzikowski J; Pearse RN; Zafar F; Pekle K; Larow A; Lent R; Mark T; Cho HJ; Shore T; Tepler J; Harpel J; Schuster MW; Mathew S; Leonard JP; Mazumdar M; Chen-Kiang S; Coleman M
Blood; 2008 Feb; 111(3):1101-9. PubMed ID: 17989313
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
Ibata S; Sato T; Kuroda H; Nagamachi Y; Iyama S; Fujimi A; Kamihara Y; Konuma Y; Yoshida M; Tatekoshi A; Hashimoto A; Horiguchi H; Ono K; Murase K; Takada K; Miyanishi K; Kobune M; Hirayama Y; Kato J
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1041-1049. PubMed ID: 27738809
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
19. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Kumar S; Flinn I; Richardson PG; Hari P; Callander N; Noga SJ; Stewart AK; Turturro F; Rifkin R; Wolf J; Estevam J; Mulligan G; Shi H; Webb IJ; Rajkumar SV
Blood; 2012 May; 119(19):4375-82. PubMed ID: 22422823
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Wang M; Martin T; Bensinger W; Alsina M; Siegel DS; Kavalerchik E; Huang M; Orlowski RZ; Niesvizky R
Blood; 2013 Oct; 122(18):3122-8. PubMed ID: 24014245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
